QQQ $ 635.55 $ 0.00 (0 %)
DIA $ 479.57 $ 0.96 (0.2 %)
SPY $ 688.40 $ -0.31 (-0.05 %)
TLT $ 91.75 $ -0.14 (-0.15 %)
GLD $ 368.77 $ -0.85 (-0.23 %)
$ 0.0002
-- x --
-- x --
-- - --
$ 0.00 - $ 0.00
1,000
na
nm
$ 1.39
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

 the-daily-biotech-pulse-veru-shares-up-on-covid-candidate-update-fda-approves-lillys-covid-treatment-latest-on-sanofi-astrazeneca-rsv-vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

Core News & Articles

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Core News & Articles

 BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company or "Bioasis"), a biopharmaceutical company develo...

Core News & Articles
BIOAF: Third Quarter Results
01/31/2022 16:00:00

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Core News & Articles
BIOAF: Second Quarter Update
11/03/2021 16:35:00

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Core News & Articles

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Core News & Articles

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION